CN109310752B - 提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 - Google Patents
提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 Download PDFInfo
- Publication number
- CN109310752B CN109310752B CN201680081646.4A CN201680081646A CN109310752B CN 109310752 B CN109310752 B CN 109310752B CN 201680081646 A CN201680081646 A CN 201680081646A CN 109310752 B CN109310752 B CN 109310752B
- Authority
- CN
- China
- Prior art keywords
- rsv
- protein
- seq
- recombinant
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 728
- 230000035772 mutation Effects 0.000 title claims abstract description 344
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 77
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 66
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 44
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 44
- 239000002157 polynucleotide Substances 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000002773 nucleotide Substances 0.000 claims description 220
- 125000003729 nucleotide group Chemical group 0.000 claims description 219
- 108090000623 proteins and genes Proteins 0.000 claims description 207
- 238000012217 deletion Methods 0.000 claims description 108
- 230000037430 deletion Effects 0.000 claims description 108
- 239000002299 complementary DNA Substances 0.000 claims description 95
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 claims description 80
- 101710144128 Non-structural protein 2 Proteins 0.000 claims description 80
- 101710199667 Nuclear export protein Proteins 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 230000004048 modification Effects 0.000 claims description 64
- 238000012986 modification Methods 0.000 claims description 64
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 208000015181 infectious disease Diseases 0.000 claims description 47
- 238000006467 substitution reaction Methods 0.000 claims description 47
- 230000002458 infectious effect Effects 0.000 claims description 38
- 108020004705 Codon Proteins 0.000 claims description 33
- 108091006027 G proteins Proteins 0.000 claims description 30
- 108091000058 GTP-Binding Proteins 0.000 claims description 30
- 241000282414 Homo sapiens Species 0.000 claims description 27
- 102000030782 GTP binding Human genes 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 22
- 102220226361 rs1064794680 Human genes 0.000 claims description 18
- 101710141454 Nucleoprotein Proteins 0.000 claims description 15
- 230000029812 viral genome replication Effects 0.000 claims description 14
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007923 nasal drop Substances 0.000 claims description 3
- 229940100662 nasal drops Drugs 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 102220059225 rs748406142 Human genes 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 102220082314 rs863224177 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 298
- 101150103632 M2-2 gene Proteins 0.000 abstract description 89
- 229960005486 vaccine Drugs 0.000 abstract description 78
- 230000014509 gene expression Effects 0.000 abstract description 38
- 230000010076 replication Effects 0.000 description 91
- 241000282552 Chlorocebus aethiops Species 0.000 description 75
- 230000000875 corresponding effect Effects 0.000 description 60
- 241001465754 Metazoa Species 0.000 description 34
- 101150107578 SH gene Proteins 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 230000005847 immunogenicity Effects 0.000 description 28
- 230000002163 immunogen Effects 0.000 description 27
- 230000003612 virological effect Effects 0.000 description 26
- 238000001514 detection method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 210000003501 vero cell Anatomy 0.000 description 23
- 239000002054 inoculum Substances 0.000 description 22
- 230000003472 neutralizing effect Effects 0.000 description 22
- 241000711920 Human orthopneumovirus Species 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 229940124679 RSV vaccine Drugs 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 14
- 230000000241 respiratory effect Effects 0.000 description 14
- 210000002345 respiratory system Anatomy 0.000 description 14
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 13
- 241000282412 Homo Species 0.000 description 13
- 101710128560 Initiator protein NS1 Proteins 0.000 description 13
- 101150039699 M2-1 gene Proteins 0.000 description 13
- 101710144127 Non-structural protein 1 Proteins 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 241000282579 Pan Species 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108091023045 Untranslated Region Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000014621 translational initiation Effects 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 208000020007 Autosomal agammaglobulinemia Diseases 0.000 description 9
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229940125575 vaccine candidate Drugs 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020005350 Initiator Codon Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 102220353319 c.196A>G Human genes 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 102220281779 rs1555594471 Human genes 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 108020005038 Terminator Codon Proteins 0.000 description 6
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000711895 Bovine orthopneumovirus Species 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101150082239 G gene Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 241000711902 Pneumovirus Species 0.000 description 4
- 241000724205 Rice stripe tenuivirus Species 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102200025714 rs11541494 Human genes 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 3
- 108091029795 Intergenic region Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 101150095629 NS2 gene Proteins 0.000 description 3
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001944 turbinate Anatomy 0.000 description 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 101150034814 F gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000351643 Metapneumovirus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010070583 Vaccine virus shedding Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- -1 etc.) Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002134 immunopathologic effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000007485 viral shedding Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- 102000054566 Antiviral Restriction Factors Human genes 0.000 description 1
- 108700021236 Antiviral Restriction Factors Proteins 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- HUAOKVVEVHACHR-CIUDSAMLSA-N Asn-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N HUAOKVVEVHACHR-CIUDSAMLSA-N 0.000 description 1
- XQQVCUIBGYFKDC-OLHMAJIHSA-N Asn-Asp-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XQQVCUIBGYFKDC-OLHMAJIHSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101150046652 M2 gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- WPTDJKDGICUFCP-XUXIUFHCSA-N Met-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCSC)N WPTDJKDGICUFCP-XUXIUFHCSA-N 0.000 description 1
- KYJHWKAMFISDJE-RCWTZXSCSA-N Met-Thr-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCSC KYJHWKAMFISDJE-RCWTZXSCSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 description 1
- VWHJZETTZDAGOM-XUXIUFHCSA-N Pro-Lys-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VWHJZETTZDAGOM-XUXIUFHCSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 1
- VYTUETMEZZLJFU-IHRRRGAJSA-N Tyr-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CS)C(=O)O VYTUETMEZZLJFU-IHRRRGAJSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- KVMLCRQYXDYXDX-UHFFFAOYSA-M potassium;chloride;hydrochloride Chemical compound Cl.[Cl-].[K+] KVMLCRQYXDYXDX-UHFFFAOYSA-M 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 102200058457 rs121434643 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266199P | 2015-12-11 | 2015-12-11 | |
| US62/266,199 | 2015-12-11 | ||
| PCT/US2016/066146 WO2017100759A1 (en) | 2015-12-11 | 2016-12-12 | Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109310752A CN109310752A (zh) | 2019-02-05 |
| CN109310752B true CN109310752B (zh) | 2022-12-16 |
Family
ID=57714677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680081646.4A Active CN109310752B (zh) | 2015-12-11 | 2016-12-12 | 提供一系列减毒表型的在m2-2 orf中具有突变的重组呼吸道合胞病毒株 |
Country Status (9)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3064267A1 (en) | 2017-05-29 | 2018-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use |
| JP2023529836A (ja) * | 2020-06-05 | 2023-07-12 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 生弱毒化呼吸器合胞体ウイルス |
| WO2025106787A1 (en) | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Trehalose vaccine formulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3224404A1 (de) | 1982-06-30 | 1984-01-05 | LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl | Reibungskupplung sowie verfahren zu deren montage |
| US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US6264957B1 (en) | 1995-09-27 | 2001-07-24 | The United States Of America As Represented By The Department Of Health And Human Services | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| US20040005542A1 (en) * | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
| AU2002236522B2 (en) * | 2000-11-28 | 2007-10-25 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| DE10118446A1 (de) * | 2001-04-12 | 2002-10-17 | Thomas Hartung | Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen |
| WO2013154728A1 (en) | 2012-04-13 | 2013-10-17 | The United States Of America , As Represented By The Secretary, Department Of Health And Human Services | Genetically stable live attenuated respiratory syncytial virus vaccine and its production |
| US20160228536A1 (en) * | 2013-09-18 | 2016-08-11 | Medimmune, Llc | Recombinant respiratory syncytial virus (rsv) and vaccines |
| US10947512B2 (en) | 2015-08-14 | 2021-03-16 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered NS1 protein function and related materials and methods |
-
2016
- 2016-12-12 CA CA3007408A patent/CA3007408A1/en active Pending
- 2016-12-12 AU AU2016366771A patent/AU2016366771B2/en active Active
- 2016-12-12 JP JP2018530548A patent/JP7079197B2/ja active Active
- 2016-12-12 CN CN201680081646.4A patent/CN109310752B/zh active Active
- 2016-12-12 WO PCT/US2016/066146 patent/WO2017100759A1/en active Application Filing
- 2016-12-12 US US16/061,314 patent/US10655109B2/en active Active
- 2016-12-12 BR BR112018011674-2A patent/BR112018011674A2/pt active Search and Examination
- 2016-12-12 AR ARP160103793A patent/AR106956A1/es unknown
- 2016-12-12 EP EP16822321.2A patent/EP3386539A1/en active Pending
-
2020
- 2020-05-18 US US16/877,277 patent/US11332721B2/en active Active
-
2022
- 2022-03-01 JP JP2022030778A patent/JP7357709B2/ja active Active
Non-Patent Citations (3)
| Title |
|---|
| Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells;BUKREYEV A 等;《JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY》;20011201;第75卷(第24期);12128-12140 * |
| Respiratory Syncytial Virus That Lacks Open Reading Frame 2 of the M2 Gene (M2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents;HONG JIN等;《JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY》;20000101;第79卷(第1期);74-82 * |
| The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription;BERMINGHAM ALISON等;《PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES》;19990928;第96卷(第20期);11259–11264 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11332721B2 (en) | 2022-05-17 |
| AU2016366771A1 (en) | 2018-07-12 |
| WO2017100759A1 (en) | 2017-06-15 |
| AR106956A1 (es) | 2018-03-07 |
| JP2018536428A (ja) | 2018-12-13 |
| JP2022088376A (ja) | 2022-06-14 |
| CA3007408A1 (en) | 2017-06-15 |
| US10655109B2 (en) | 2020-05-19 |
| US20190040365A1 (en) | 2019-02-07 |
| US20200283740A1 (en) | 2020-09-10 |
| RU2018125246A3 (enrdf_load_stackoverflow) | 2020-05-25 |
| KR20180085803A (ko) | 2018-07-27 |
| RU2018125246A (ru) | 2020-01-15 |
| EP3386539A1 (en) | 2018-10-17 |
| JP7079197B2 (ja) | 2022-06-01 |
| JP7357709B2 (ja) | 2023-10-06 |
| AU2016366771B2 (en) | 2022-04-07 |
| CN109310752A (zh) | 2019-02-05 |
| BR112018011674A2 (pt) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021218112B2 (en) | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes | |
| CN101012454B (zh) | 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法 | |
| AU2020203460B2 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
| US6689367B1 (en) | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences | |
| CN113322264B (zh) | 具有沉默突变的重组rsv、其相关疫苗和方法 | |
| KR20110063863A (ko) | 생 약독화 호흡기 세포융합 바이러스 | |
| KR100746979B1 (ko) | 클로닝된 뉴클레오티드 서열로부터의 약독화된 키메릭호흡기 신시티움 바이러스 백신의 제조 | |
| JP7357709B2 (ja) | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 | |
| KR20210005090A (ko) | 키메라 벡터 | |
| CN108699535B (zh) | 包含ns1和ns2基因迁移的重组呼吸道合胞病毒株 | |
| KR20230021115A (ko) | 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus) | |
| KR102854980B1 (ko) | 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주 | |
| KR20230038205A (ko) | 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법 | |
| KR20250134719A (ko) | 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주 | |
| RU2773746C2 (ru) | Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов | |
| AU5591601A (en) | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |